Study identifier:D1449L00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An open, randomised, parallel, three treatment groups, multicentre, phase IV study - in real life - to compare the change in social outcome of quetiapine fumarate (Seroquel®) combined with Cognitive Remediation Therapy to conventional treatment in patients with schizophrenia.
schizophrenia
Phase 4
No
Quetiapine fumarate, conventional treatment for schizophrenia
All
85
Interventional
18 Years - 64 Years
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to compare efficacy of quetiapine fumarate combined with Cognitive Remediation Therapy (CRT) to conventional treatment by evaluating change in social outcome in patients with schizophrenia.
Location
Location
ESKILSTUNA, Sweden
Location
GÖTEBORG, Sweden
Location
HUDDINGE, Sweden
Location
JÖNKÖPING, Sweden
Location
LIMHAMN, Sweden
Location
LUND, Sweden
Location
MALMÖ, Sweden
Location
NORSBORG, Sweden
Arms | Assigned Interventions |
---|---|
Experimental: 1 quetiapine fumarate | Drug: Quetiapine fumarate oral Other Name: Seroquel |
Active Comparator: 2 Conventional treatment for schizophrenia | Drug: conventional treatment for schizophrenia various standard therapies |
Experimental: 3 quetiapine fumarate + Cognitive Remediation Therapy | Drug: Quetiapine fumarate oral Other Name: Seroquel |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.